However, consistent with the design of Beat AML Master Trial and the general standard of care, patients with other targetable mutations (e.g., FLT3-ITD) with complex karyotype and/or mutant TP53 were effectively excluded from the present trial. The gene discussed is TP53; the disease is acute myeloid leukemia.